From CAR-MSC to miRNA inhibition of #CART , Olivia Sirpilla is knocking it out of the park! Come check out her award winning poster #AACR24 eppro01.ativ.me/appinfo.php?pa… #AACR24 Mayo Clinic Comprehensive Cancer Center

My doctoral paper, which introduces a novel cell therapy platform CAR-MSCs for treatment of immune disease has been published in #Nature Biomedical Engineering! Thankful to my mentor Saad kenderian and our TCEP lab team at Mayo for making this possible.
nature.com/articles/s4155…

More important work on Richter Transformation. Currently, I am using venetoclax + RCHOP as front line therapy in most pts. A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia. ashpublications.org/bloodadvances/…

Engineering mesenchymal stromal cells with designer chimeric antigen receptors (CAR-MSCs) with enhanced immunosuppressive functions | Nature Biomedical Engineering 2024 Nature Biomedical Engineering | excited to translate to clinic #car #gvhd #ibd nature.com/articles/s4155…

The heart and soul of our transplant program - our coordinators!!! ⁦The James⁩ ⁦Ohio State Nursing⁩ ⁦OSU Hematology⁩ ⁦The Ohio State University Wexner Medical Center⁩

A multicenter study of posttransplant low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia ashpublications.org/bloodadvances/…

Thank you Robert Spinner, MD I am excited to elevate and support our #medical #education learners & faculty Mayo Clinic Alix School of Medicine Students of Mayo MSTP @MayoClinic Mayo Clinic Graduate School of Biomedical Sciences Mayo Clinic Med Ed

#Tandem24 ⁦ASTCT⁩ ⁦Sarah Wall, MD MPH⁩ Proud of Justin Tossey, our amazing specialty pharmacist speaking on CMV therapy ! Even if you missed the live session, catch up on the recording.

In this case series of 15 patients with severe autoimmune disease, selective deep depletion of B lymphocytes with CD19 CAR T-cell therapy was effective in achieving clinical remission. Read the full article: nej.md/3UMQcMH

Starring yours truly and the brilliant Mohammad Alhomoud... the podcast you've all been waiting for! Chimerically Speaking presents: Episode 1: Off to #Tandem24 . We'll be bringing you interviews and discussions from across the field as we grow The Pod.
shows.acast.com/chimerically-s…

I am excited to share with you our new podcast! If you, like us, fascinated with how transplant and cellular therapy field has evolved, and you enjoy listening to the stories of brilliant scientists and leaders- then follow Chimerically Speaking #bmtsm #CellularTherapy more to come!

Check out this podcast from #ASH23 in which Dr. Evandro Bezerra discusses his team's #research regarding real-world #outcomes of #brexucabtagene autoleucel ( #brexucel ) for B-cell acute lymphoblastic #leukemia ( #ALL )! oncdata.com/news/real-worl…

Check out the complete playlist of #ASH23 podcasts from #OncData ! Hear fascinating conversations with Evandro Bezerra, Rahul Banerjee, MD, FACP, Gurbakhash Kaur, Richa Parikh, Richa Thakur, MD, Richard Newcomb, Urvi Shah, and more esteemed researchers!

oncdata.com/news/oncology-…

ASH

🔬 Evandro Bezerra, MD The Ohio State University Wexner Medical Center, unveils groundbreaking insights on brexu-cel in adult B-cell ALL. Explore eligibility challenges, treatment impacts, and safety nuances in this transformative study. 🌟 [Video] oncologytube.com/channel/ASH/vi… #ASH2023 #Hematology #LeukemiaResearch

Targeted Top 5: Top Stories From This Week! Evandro Bezerra, OSU Hematology, The James
ASH, Andrew Srisuwananukorn, Peter Mac Research UCLA Health

1. targetedonc.com/view/real-worl…
2. targetedonc.com/view/targeted-…
3. targetedonc.com/view/utilizing…
4.targetedonc.com/view/bgb-16673…
5. targetedonc.com/view/pembroliz…

#ASH23 ⁦Evandro Bezerra⁩ presenting brexu-cel outcomes as reported to ⁦CIBMTR⁩ ⁦The James⁩

If you see an eligible DLBCL patient in CR, does #CART outperform AutoHCT? Only available data by CIBMTR Mazyar Shadman, MD MPH Reminds you to keep an open mind,
one size does not fit all 🙏🙏 ASH for recognizing our work in Press Release #ASH23

What a great day 1 at #ASH23 ! Thanks to all the great experts who stopped by to drop some knowledge! Can’t wait for tomorrow! Evandro Bezerra The James Dr. Minoo Battiwalla Sarah Cannon Docs Memorial Sloan Kettering Cancer Center ASH

OncData had the pleasure of speaking with Dr. Evandro Bezerra (Evandro Bezerra) of OSU Hematology about his study 'Real-World Outcomes of #BrexuCel for R/R B-Cell #ALL . Stay tuned to hear the podcast!

At #ASH23 , Evandro D. Bezerra, MD, provides real-world data from the CIBMTR Registry, examining the effectiveness of brexu-cel for the treatment of patients with relapsed/refractory B-cell #ALL . #LEUSM | Evandro Bezerra OSU Hematology The James

targetedonc.com/view/real-worl…